Adam S. Mostafa Sells 74,773 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $0.48 on Wednesday. The firm has a market cap of $82.17 million, a P/E ratio of -5.35 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 52-week low of $0.26 and a 52-week high of $1.60. The business’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.61. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of XFOR. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the third quarter worth $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals in the third quarter valued at about $37,000. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals in the second quarter valued at about $65,000. Rhumbline Advisers increased its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the period. Finally, Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after purchasing an additional 126,296 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

XFOR has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a research report on Tuesday, January 14th. Stifel Nicolaus dropped their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.